SCYNEXIS, Inc. (SCYX)

CIK 0001178253 · Healthcare · Drug Manufacturers

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q1-2026 —
Latest FY-2025 —
Q3-2025 —
Q2-2025 —
Q1-2025 —
FY-2024 —
Q3-2024 —
Q2-2024 —
Q1-2024 —
FY-2023 8-K (2024-03-28) · 99.1
Q3-2023 —
Q2-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Balance Sheets
—
Unaudited Condensed Consolidated Balance Sheets
—
Consolidated Balance Sheets (P)
—
Unaudited Condensed Consolidated Balance Sheets (P)
—
Consolidated Statements of Operations
—
Unaudited Condensed Consolidated Statements of Operations
—
Consolidated Statements of Changes In Stockholders' Equity
—
Unaudited Condensed Consolidated Statements of Cash Flows
—
Consolidated Statements of Cash Flows
—
Notes
Accrued Expenses
Asset Purchase Agreement
—
Borrowings
Borrowings and Contingencies
—
Commitments and Contingencies
Commitments, Contingencies, and Borrowings
—
Contingencies and Borrowings
—
Cybersecurity Risk Management, Strategy, and Governance
—
Description of Business and Basis of Preparation
Employee Benefit Plan
—
Fair Value Measurements
Income Taxes
—
Insider Trading Arrangements
Intangible Assets
—
Inventory
Investments
Pay Vs Performance Disclosure
Prepaid Expenses and Other Current Assets
Revenue
Securities Purchase Agreement
—
Segments
Stock-based Compensation
Stockholders' Equity
Subsequent Events
Summary of Significant Accounting Policies